As of 2026-08-15, the EV/EBITDA ratio of Nuvo Pharmaceuticals Inc (MRV.TO) is 13,222.79. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRV.TO's latest enterprise value is 258,598.06 mil CAD. MRV.TO's TTM EBITDA according to its financial statements is 19.56 mil CAD. Dividing these 2 quantities gives us the above MRV.TO EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 19.6x | 11.8x |
| Forward P/E multiples | 6.7x - 11.0x | 9.2x |
| Fair Price | 0.01 - 0.04 | 0.02 |
| Upside | -100.0% - -99.9% | -99.9% |
| Date | EV/EBITDA |
| 2026-08-11 | 12,650.75 |
| 2026-08-10 | 12,438.06 |
| 2026-08-07 | 13,039.44 |
| 2026-08-06 | 12,573.74 |
| 2026-08-05 | 12,577.41 |
| 2026-08-04 | 13,046.78 |
| 2026-07-31 | 11,187.64 |
| 2026-07-30 | 10,934.62 |
| 2026-07-29 | 9,750.20 |
| 2026-07-28 | 10,399.25 |
| 2026-07-27 | 11,282.98 |
| 2026-07-24 | 11,594.67 |
| 2026-07-23 | 12,485.73 |
| 2026-07-22 | 12,610.41 |
| 2026-07-21 | 12,416.06 |
| 2026-07-20 | 11,646.01 |
| 2026-07-17 | 11,279.31 |
| 2026-07-16 | 11,268.31 |
| 2026-07-15 | 12,306.05 |
| 2026-07-14 | 13,288.79 |
| 2026-07-13 | 12,999.10 |
| 2026-07-10 | 14,069.85 |
| 2026-07-09 | 14,498.88 |
| 2026-07-08 | 13,820.50 |
| 2026-07-07 | 13,798.50 |
| 2026-07-06 | 14,887.58 |
| 2026-07-03 | 15,312.94 |
| 2026-07-02 | 14,726.23 |
| 2026-06-30 | 17,791.79 |
| 2026-06-29 | 16,545.03 |
| 2026-06-26 | 15,943.66 |
| 2026-06-25 | 16,834.72 |
| 2026-06-24 | 16,622.04 |
| 2026-06-23 | 16,684.38 |
| 2026-06-22 | 18,422.50 |
| 2026-06-19 | 19,328.24 |
| 2026-06-18 | 18,576.52 |
| 2026-06-17 | 17,238.08 |
| 2026-06-16 | 16,688.04 |
| 2026-06-15 | 18,550.85 |
| 2026-06-12 | 16,798.05 |
| 2026-06-11 | 16,787.05 |
| 2026-06-10 | 15,107.59 |
| 2026-06-09 | 15,954.66 |
| 2026-06-08 | 17,293.09 |
| 2026-06-05 | 15,771.31 |
| 2026-06-04 | 18,983.55 |
| 2026-06-03 | 18,081.48 |
| 2026-06-02 | 17,425.10 |
| 2026-06-01 | 13,116.45 |